On Friday, Shares of Bristol-Myers Squibb Co (NYSE:BMY), gained 1.55% to $61.45.
Bristol-Myers Squibb Company, declared that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR mutation or ALK translocation should have disease progression on appropriate targeted therapy preceding to receiving Opdivo. In a Phase 3 trial, CheckMate -057, Opdivo demonstrated superior overall survival (OS) in formerly treated metastatic non-squamous NSCLC contrast to chemotherapy, with a 27% reduction in the risk of death (hazard ratio: 0.73 [95% CI: 0.60, 0.89; p=0.0015]), based on a prespecified interim analysis.1 The median OS was 12.2 months in the Opdivo arm (95% CI: 9.7, 15.0) and 9.4 months in the docetaxel arm (95% CI: 8.0, 10.7).1 This approval expands Opdivo’s indication for formerly treated metastatic squamous NSCLC to comprise the non-squamous patient population. Squamous and non-squamous NSCLC together represent about 85% to 90% of lung cancer cases.
Opdivo is associated with immune-mediated: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, rash, encephalitis, other adverse reactions; infusion reactions; and embryofetal toxicity.1 Please see the Important Safety Information section below.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Shares of Atmel Corporation (NASDAQ:ATML), inclined 0.47% to $8.57, during its last trading session.
Cypress Semiconductor Corp., issued the following statement in response to recent market rumors regarding Atmel Corporation (ATML).
Cypress formerly presented an offer to the Board of Directors of Atmel to acquire Atmel. That offer expired and Cypress has withdrawn its interest in an acquisition of Atmel. Cypress regularly evaluates acquisition opportunities to complement its existing business, and maintains a disciplined approach to ensure that it continues to deliver long-term value to its shareholders.
Atmel Corporation designs, develops, manufactures, and sells semiconductor integrated circuit products primarily in the United States, Asia, Europe, South Africa, and Central and South America. It operates in four segments: Microcontroller, Nonvolatile Memory, Automotive, and Multi-Market and Other.
Finally, CONSOL Energy Inc. (NYSE:CNX), ended its last trade with 0.95% gain, and closed at $11.71.
CONE Midstream Partners, declared that it will release financial results for the third quarter of 2015 before market opening on Tuesday, November 3, 2015 and hold a conference call to discuss those results on the same day at 1:00 p.m. Eastern Time. The conference call will be publicly available via webcast on a live and replay basis.
Interested parties are invited to listen to the conference call, during which prepared remarks by John T. Lewis, Chairman and Chief Executive Officer, and other members of administration will be followed by a question and answer session. Participants who would like to ask questions during the conference call may join by phone. Individuals who intend to listen only are encouraged to join the conference via the Internet.
CONSOL Energy Inc., together with its auxiliaries, operates as an integrated energy company in the United States and internationally. The company operates through two divisions, Exploration and Production (E&P), and Coal.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
